尽管在癌症细胞疗法方面开展了工作,但适应性免疫素治疗方法面临各种分析家观点的混杂和降级。 Adaptimmune Therapeutics faces mixed analyst views and a downgrade, despite working on cancer cell therapies.

适应性免疫疗法(NASDAQ:ADAP)面临各种不同的分析意见,平均提出“坚持”建议,12个月的价格目标是1.35美元。 Adaptimmune Therapeutics (NASDAQ: ADAP) faces mixed analyst views, with an average "Hold" recommendation and a 12-month price target of $1.35. 该公司最近报告了负面金融指标,包括38.91%的净差值和163.73%的股本回报率。 The company recently reported negative financial metrics, including a 38.91% net margin and 163.73% return on equity. Mizuho将其评分降为“中性”,目标价格降低为0.50美元。 Mizuho downgraded its rating to "neutral" with a lower target price of $0.50. 适应性免疫侧重于为美国和联合王国的癌症病人开发细胞疗法,目前正在进行若干临床试验。 Adaptimmune focuses on developing cell therapies for cancer patients in the US and UK, with several clinical trials in progress.